Published in Int Neurourol J on November 22, 2016
Are We Ready to Use the Omics Strategies for Precision Medicine? Int Neurourol J (2016) 0.75
Translating the histone code. Science (2001) 56.77
Chromatin modifications and their function. Cell (2007) 55.98
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science (2011) 13.16
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science (2007) 12.42
Evidence for nucleosome depletion at active regulatory regions genome-wide. Nat Genet (2004) 9.10
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (1985) 8.32
Epigenetics in cancer. Carcinogenesis (2009) 7.49
p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell (1994) 7.05
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet (1999) 5.29
DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet (2000) 5.09
Nucleosomes inhibit the initiation of transcription but allow chain elongation with the displacement of histones. Cell (1987) 5.00
Bladder cancer. Lancet (2009) 4.43
Association between smoking and risk of bladder cancer among men and women. JAMA (2011) 4.31
Rethinking how DNA methylation patterns are maintained. Nat Rev Genet (2009) 4.03
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat Genet (2007) 3.63
Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol (2002) 3.61
Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer (2001) 3.61
TET enzymes, TDG and the dynamics of DNA demethylation. Nature (2013) 3.49
Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet (2012) 3.08
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene (2005) 2.66
Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol (2005) 2.45
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet (2013) 2.44
Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet (2012) 2.35
Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res (2003) 2.34
Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell (2014) 2.28
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Urine markers for bladder cancer surveillance: a systematic review. Eur Urol (2005) 1.90
Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res (2001) 1.84
A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res (2007) 1.77
Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol (2008) 1.75
Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol (2013) 1.74
Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining. Mol Cell (2014) 1.72
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell (2016) 1.69
E2F-Rb complexes regulating transcription of genes important for differentiation and development. Curr Opin Genet Dev (2005) 1.66
FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res (2003) 1.64
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol (2016) 1.64
Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res (2010) 1.62
Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess (2010) 1.62
Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur Urol (2011) 1.55
Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin Cancer Res (2012) 1.50
Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res (2010) 1.47
Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res (2011) 1.46
Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res (2005) 1.40
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev (2009) 1.26
Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res (2002) 1.24
Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol Cell Biol (1994) 1.22
Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev (2011) 1.19
Trials with 'epigenetic' drugs: an update. Mol Oncol (2012) 1.19
Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene (2009) 1.17
Targeted therapies in urothelial carcinoma. Curr Opin Oncol (2014) 1.15
Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A (2014) 1.14
4-aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis (2002) 1.12
Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene (2006) 1.12
Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol (2011) 1.11
LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol Biomarkers Prev (2008) 1.08
Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis (2004) 1.07
Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urology (2009) 1.05
Models of carcinogenesis: an overview. Carcinogenesis (2010) 1.05
DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol (2013) 1.05
Vitamin C deficiency in cancer patients. Palliat Med (2005) 1.05
A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst (2010) 1.02
Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol (2001) 1.01
A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res (2014) 0.99
Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur Urol (2012) 0.98
Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene (2000) 0.96
Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics (2015) 0.96
A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity. J Biol Chem (1997) 0.95
Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine. Proc Natl Acad Sci U S A (2016) 0.95
The role of DNA methylation in directing the functional organization of the cancer epigenome. Genome Res (2015) 0.94
Bladder cancer. Curr Opin Oncol (2011) 0.94
ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol (2005) 0.93
Bivalent Regions of Cytosine Methylation and H3K27 Acetylation Suggest an Active Role for DNA Methylation at Enhancers. Mol Cell (2016) 0.91
Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer. Adv Urol (2012) 0.90
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res (2015) 0.88
Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a critical review. Clin Rev Allergy Immunol (2014) 0.84
The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol (2014) 0.83
Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer. Urol Int (2014) 0.81
Urine microRNAs as biomarkers for bladder cancer: a diagnostic meta-analysis. Onco Targets Ther (2015) 0.81
Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk. Nat Commun (2016) 0.80
Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma. Oncotarget (2015) 0.80
DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells. Nat Commun (2016) 0.80
Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies. PLoS One (2016) 0.79
BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder. Eur Urol (1999) 0.78
Epigenetic alterations in bladder cancer and their potential clinical implications. Adv Urol (2012) 0.77
Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing. Oncotarget (2016) 0.77
Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2'-deoxycytidine. Sci Rep (2016) 0.76